A Review of Osteoporosis in the Older Adult: An Update

被引：60

作者：

Alejandro, Paloma ^{[1
]}

Constantinescu, Florina ^{[1
]}

机构：

[1] Georgetown Univ, Med Ctr, MedStar Washington Hosp Ctr, Div Rheumatol, 110 Irving St Northwest 2A-66, Washington, DC 20010 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2018年 / 44卷 / 03期

关键词：

Osteoporosis; Bisphosphonates; FRAX; Drug holiday; Hip fractures; Elderly; DXA; BONE-MINERAL DENSITY; ZOLEDRONIC ACID TREATMENT; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; FRACTURE RISK; VERTEBRAL FRACTURES; RANDOMIZED-TRIAL; ORAL IBANDRONATE; HIP FRACTURE; MEN;

D O I：

10.1016/j.rdc.2018.03.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoporosis in the elderly population is common. It results in more than 1.5 million fractures per year in the United States. The goal of managing osteoporosis is to prevent fractures. In men, osteoporosis is underrecognized and undertreated. More men than women die every year as a consequence of hip fractures. Bisphosphonates are the first-line treatment of men and women. In the past several years, advances in bone biology have resulted in major therapeutic advances. This article reviews the diagnosis and treatment of osteoporosis.

引用

页码：437 / +

页数：16

共 70 条

[1] ABBASI AA, 1995, AM J MED SCI, V310, P229
[2] Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone
Amory, JK
Watts, NB
Easley, KA
Sutton, PR
Anawalt, BD
Matsumoto, AM
Bremner, WJ
Tenover, JL
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) : 503 - 510
[3] [Anonymous], REC DXA MAN FRAX IMP
[4] Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study
Bauer, Douglas C.
Schwartz, Ann
Palermo, Lisa
Cauley, Jane
Hochberg, Marc
Santora, Art
Cummings, Steven R.
Black, Dennis M.
[J]. JAMA INTERNAL MEDICINE, 2014, 174 (07) : 1126 - 1134
[5] Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, HM
Kliesch, S
Leifke, E
Link, TM
Nieschlag, E
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (08) : 2386 - 2390
[6] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Black, Dennis M.
Delmas, Pierre D.
Eastell, Richard
Reid, Ian R.
Boonen, Steven
Cauley, Jane A.
Cosman, Felicia
Lakatos, Peter
Leung, Ping Chung
Man, Zulema
Mautalen, Carlos
Mesenbrink, Peter
Hu, Huilin
Caminis, John
Tong, Karen
Rosario-Jansen, Theresa
Krasnow, Joel
Hue, Trisha F.
Sellmeyer, Deborah
Eriksen, Erik Fink
Cummings, Steven R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) : 1809 - 1822
[7] Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
[8] The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Black, Dennis M.
Reid, Ian R.
Cauley, Jane A.
Cosman, Felicia
Leung, Ping Chung
Lakatos, Peter
Lippuner, Kurt
Cummings, Steven R.
Hue, Trisha F.
Mukhopadhyay, Amitava
Tan, Monique
Aftring, R. Paul
Eastell, Richard
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (05) : 934 - 944
[9] Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long?
Black, Dennis M.
Bauer, Douglas C.
Schwartz, Ann V.
Cummings, Steven R.
Rosen, Clifford J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) : 2051 - 2053
[10] The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Black, Dennis M.
Reid, Ian R.
Boonen, Steven
Bucci-Rechtweg, Christina
Cauley, Jane A.
Cosman, Felicia
Cummings, Steven R.
Hue, Trisha F.
Lippuner, Kurt
Lakatos, Peter
Leung, Ping Chung
Man, Zulema
Martinez, Ruvie Lou Maria
Tan, Monique
Ruzycky, Mary Ellen
Su, Guoqin
Eastell, Richard
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) : 243 - 254

← 1 2 3 4 5 6 7 →